Study details
Enrolling now
Combination Therapy for Pancreatic Cancer
Gulam Manji
NCT IDNCT06048484ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 3 years
Ages
18+
Locations
5 sites in NC, NY, PA +1
What this study is about
This trial is testing a combination of drugs, radiation therapy, and immunotherapy to treat localized pancreatic cancer. The goal is to see if this treatment approach can safely boost the immune system's ability to fight the tumor.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Stereotactic body radiotherapy (SBRT)
- 2.Take Etrumadenant
- 3.Take Modified FOLFIRINOX
- +2 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
chemotherapy
Drug routes
infusion
Endpoints
Secondary: Count of Grade 3 or Higher Adverse Events, Overall Survival, Pathologic Complete Response Rate, Recurrence free survival